Androgen deprivation therapy (ADT) remains the cornerstone of prostate cancer treatment. LHRH agonists and antagonists are widely used to suppress testosterone production. First-generation antiandrogens, such as bicalutamide, block androgen receptor activation, while second-generation antiandrogens, like enzalutamide and apalutamide, offer more potent inhibition of androgen receptor signaling. Abiraterone, a CYP17 inhibitor, blocks testosterone biosynthesis. While these therapies are effective, side effects are common, wide ranging and troublesome. Despite advancing therapies for prostate cancer, castrate resistance is still common.